← Back to Search

Photothermal Treatment

577-nm PASCAL laser for Macular Telangiectasia

N/A

Waitlist Available

Research Sponsored by The Lowy Medical Research Institute Limited

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing a new treatment for macular telangiectasia type 2, a degenerative eye disease. One group will receive the new treatment while the other group will receive a sham procedure. Data will be collected over the course of a year to see if the new treatment is effective.

Eligible Conditions

Macular Telangiectasia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Secondary outcome measures

Change from baseline cone density as measured by confocal adaptive optics (AOSLO)

Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)

Development or extension post therapy of areas of deficiency in cones as measured by AOSLO

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Subthreshold Photothermal TherapyExperimental Treatment1 Intervention

Group II: ShamPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

577-nm PASCAL laser

2018

N/A

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The Lowy Medical Research Institute LimitedLead Sponsor

5 Previous Clinical Trials

178 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to be a part of this clinical experiment?

"This research trial seeks to recruit 9 individuals between 21 and 79 years old with Macular Telangiectasia. To be eligible, patients must provide their written consent according to local regulations; have an Ellipsoid Zone break in the study eye of 0.16-4.0 mm2 as measured on SD-OCT, a best corrected visual acuity of at least 55 letters (20/80) in the study eye; demonstrate steady fixation within foveal or parafoveal area of each eye; possess adequate pupil dilation and sufficiently clear media for multi-modal retinal imaging and treatment; attend all"

Answered by AI

Are there still enrolment opportunities for this trial?

"According to the clinicaltrials.gov database, this experiment is no longer accepting participants at present time -- the initial posting was on 2/8/2018 and it was last modified on 11/3/2022. Nevertheless, there are 20 active trials that require volunteers right now."

Answered by AI